Nanomedicines for oral administration based on diverse nanoplatform

Taehoon Sim; Chaemin Lim; Ngoc Ha Hoang; Hyonsung Joo; Jun Won Lee; Da won Kim; Eun Seong Lee; Yu Seok Youn; Jong Oh Kim; Kyung Taek Oh

doi:10.1007/s40005-016-0255-y

Nanomedicines for oral administration based on diverse nanoplatform

Taehoon Sim, Chaemin Lim, Ngoc Ha Hoang, Hyonsung Joo, Jun Won Lee, Da won Kim, Eun Seong Lee, Yu Seok Youn, Jong Oh Kim, Kyung Taek Oh

Department of Biomedical-Chemical Engineering

Research output: Contribution to journal › Review article › peer-review

44 Scopus citations

Abstract

Nanotechnology has been applied to the oral drug delivery for enhancing bioavailability after oral administration. Numerous forms of reported nanomedicines are classified as lipid based nanomedicine (LBNM), polymer based nanomedicine (PBNM), and nanosuspension. LBNM includes self nano-emulsifying drug delivery systems, liposomes and solid lipid nanoparticle (SLN). PBNM includes polymeric nanoparticles and polymeric micelles. Unlike intravenous administration, oral administration has more complicated barriers that are hard to overcome. The various nanoplatforms described above are used to surmount physical and bio-chemical barriers due to advantageous characteristics of nanoplatforms. The characteristics of nanoplatforms including particle size, stimuli-sensitivity, preventing drug efflux, solubility and permeation of the drug induce the enhanced absorption and high bioavailability. Regardless of passionate researches, some limitations still exist, for instance economic problems, toxicity issue, and development of biopharmaceutic oral nanomedicine. In this review, physiological barriers in oral administration, advantages of nanomedicines, classification of oral nanomedicines, and their challenges are described concisely.

Original language	English
Pages (from-to)	351-362
Number of pages	12
Journal	Journal of Pharmaceutical Investigation
Volume	46
Issue number	4
DOIs	https://doi.org/10.1007/s40005-016-0255-y
State	Published - 1 Jul 2016

Bibliographical note

Funding Information:
This article does not contain any studies with human and animal subjects performed by any of the authors. And All authors (T Sim, C Lim, NH Hoang, H Joo, JW Lee, D Kim, ES Lee, YS Youn, JO Kim, KT Oh) declare that they have no conflict of interest. This research was supported by a Grant (15182MFDS486) from Ministry of Food and Drug Safety in 2016. This work was supported by the National Research Foundation of Korea (NRF) grant funded by the Korea government (MSIP) (NRF-2014R1A2A1A11050094), a grant from the Medical Cluster R&D Support Project of Daegu Gyeongbuk Medical Innovation Foundation, Republic of Korea (2013) (No. HT13C0011).

Publisher Copyright:
© 2016, The Korean Society of Pharmaceutical Sciences and Technology.

Keywords

Lipid based nanomedicine
Nanomedicine
Nanoplatform
Nanosuspension
Oral drug delivery
Polymer based nanomedicine

Access to Document

10.1007/s40005-016-0255-y

Cite this

@article{691bd03bff2b43c1b5173fd2d52f305e,

title = "Nanomedicines for oral administration based on diverse nanoplatform",

abstract = "Nanotechnology has been applied to the oral drug delivery for enhancing bioavailability after oral administration. Numerous forms of reported nanomedicines are classified as lipid based nanomedicine (LBNM), polymer based nanomedicine (PBNM), and nanosuspension. LBNM includes self nano-emulsifying drug delivery systems, liposomes and solid lipid nanoparticle (SLN). PBNM includes polymeric nanoparticles and polymeric micelles. Unlike intravenous administration, oral administration has more complicated barriers that are hard to overcome. The various nanoplatforms described above are used to surmount physical and bio-chemical barriers due to advantageous characteristics of nanoplatforms. The characteristics of nanoplatforms including particle size, stimuli-sensitivity, preventing drug efflux, solubility and permeation of the drug induce the enhanced absorption and high bioavailability. Regardless of passionate researches, some limitations still exist, for instance economic problems, toxicity issue, and development of biopharmaceutic oral nanomedicine. In this review, physiological barriers in oral administration, advantages of nanomedicines, classification of oral nanomedicines, and their challenges are described concisely.",

keywords = "Lipid based nanomedicine, Nanomedicine, Nanoplatform, Nanosuspension, Oral drug delivery, Polymer based nanomedicine",

author = "Taehoon Sim and Chaemin Lim and Hoang, {Ngoc Ha} and Hyonsung Joo and Lee, {Jun Won} and Kim, {Da won} and Lee, {Eun Seong} and Youn, {Yu Seok} and Kim, {Jong Oh} and Oh, {Kyung Taek}",

note = "Funding Information: This article does not contain any studies with human and animal subjects performed by any of the authors. And All authors (T Sim, C Lim, NH Hoang, H Joo, JW Lee, D Kim, ES Lee, YS Youn, JO Kim, KT Oh) declare that they have no conflict of interest. This research was supported by a Grant (15182MFDS486) from Ministry of Food and Drug Safety in 2016. This work was supported by the National Research Foundation of Korea (NRF) grant funded by the Korea government (MSIP) (NRF-2014R1A2A1A11050094), a grant from the Medical Cluster R&D Support Project of Daegu Gyeongbuk Medical Innovation Foundation, Republic of Korea (2013) (No. HT13C0011). Publisher Copyright: {\textcopyright} 2016, The Korean Society of Pharmaceutical Sciences and Technology.",

year = "2016",

month = jul,

day = "1",

doi = "10.1007/s40005-016-0255-y",

language = "English",

volume = "46",

pages = "351--362",

journal = "Journal of Pharmaceutical Investigation",

issn = "2093-5552",

publisher = "Springer Netherlands",

number = "4",

}

TY - JOUR

T1 - Nanomedicines for oral administration based on diverse nanoplatform

AU - Sim, Taehoon

AU - Lim, Chaemin

AU - Hoang, Ngoc Ha

AU - Joo, Hyonsung

AU - Lee, Jun Won

AU - Kim, Da won

AU - Lee, Eun Seong

AU - Youn, Yu Seok

AU - Kim, Jong Oh

AU - Oh, Kyung Taek

N1 - Funding Information: This article does not contain any studies with human and animal subjects performed by any of the authors. And All authors (T Sim, C Lim, NH Hoang, H Joo, JW Lee, D Kim, ES Lee, YS Youn, JO Kim, KT Oh) declare that they have no conflict of interest. This research was supported by a Grant (15182MFDS486) from Ministry of Food and Drug Safety in 2016. This work was supported by the National Research Foundation of Korea (NRF) grant funded by the Korea government (MSIP) (NRF-2014R1A2A1A11050094), a grant from the Medical Cluster R&D Support Project of Daegu Gyeongbuk Medical Innovation Foundation, Republic of Korea (2013) (No. HT13C0011). Publisher Copyright: © 2016, The Korean Society of Pharmaceutical Sciences and Technology.

PY - 2016/7/1

Y1 - 2016/7/1

N2 - Nanotechnology has been applied to the oral drug delivery for enhancing bioavailability after oral administration. Numerous forms of reported nanomedicines are classified as lipid based nanomedicine (LBNM), polymer based nanomedicine (PBNM), and nanosuspension. LBNM includes self nano-emulsifying drug delivery systems, liposomes and solid lipid nanoparticle (SLN). PBNM includes polymeric nanoparticles and polymeric micelles. Unlike intravenous administration, oral administration has more complicated barriers that are hard to overcome. The various nanoplatforms described above are used to surmount physical and bio-chemical barriers due to advantageous characteristics of nanoplatforms. The characteristics of nanoplatforms including particle size, stimuli-sensitivity, preventing drug efflux, solubility and permeation of the drug induce the enhanced absorption and high bioavailability. Regardless of passionate researches, some limitations still exist, for instance economic problems, toxicity issue, and development of biopharmaceutic oral nanomedicine. In this review, physiological barriers in oral administration, advantages of nanomedicines, classification of oral nanomedicines, and their challenges are described concisely.

AB - Nanotechnology has been applied to the oral drug delivery for enhancing bioavailability after oral administration. Numerous forms of reported nanomedicines are classified as lipid based nanomedicine (LBNM), polymer based nanomedicine (PBNM), and nanosuspension. LBNM includes self nano-emulsifying drug delivery systems, liposomes and solid lipid nanoparticle (SLN). PBNM includes polymeric nanoparticles and polymeric micelles. Unlike intravenous administration, oral administration has more complicated barriers that are hard to overcome. The various nanoplatforms described above are used to surmount physical and bio-chemical barriers due to advantageous characteristics of nanoplatforms. The characteristics of nanoplatforms including particle size, stimuli-sensitivity, preventing drug efflux, solubility and permeation of the drug induce the enhanced absorption and high bioavailability. Regardless of passionate researches, some limitations still exist, for instance economic problems, toxicity issue, and development of biopharmaceutic oral nanomedicine. In this review, physiological barriers in oral administration, advantages of nanomedicines, classification of oral nanomedicines, and their challenges are described concisely.

KW - Lipid based nanomedicine

KW - Nanomedicine

KW - Nanoplatform

KW - Nanosuspension

KW - Oral drug delivery

KW - Polymer based nanomedicine

UR - http://www.scopus.com/inward/record.url?scp=84979009443&partnerID=8YFLogxK

U2 - 10.1007/s40005-016-0255-y

DO - 10.1007/s40005-016-0255-y

M3 - Review article

AN - SCOPUS:84979009443

SN - 2093-5552

VL - 46

SP - 351

EP - 362

JO - Journal of Pharmaceutical Investigation

JF - Journal of Pharmaceutical Investigation

IS - 4

ER -

Nanomedicines for oral administration based on diverse nanoplatform

Abstract

Bibliographical note

Keywords

Access to Document

Other files and links

Fingerprint

Cite this